Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04849728 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT04849728 · ClinicalTrials.gov record · last posted 2026-07-02

A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )

Study acronym: NATiV3
StatusActive, Not Recruiting
PhasePhase 3
Started2021-08-19
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis histological stage F2 or F3

Protocol amendment history 6 changes detected by DataLookout

2026-05-21
Trial sites expanded: 434 → 459 locations
2026-05-21
Primary completion pushed: 2027-06-30 → 2027-09-30
2026-05-21
Completion pushed: 2027-06-30 → 2027-09-30
2026-05-16
Trial sites expanded: 428 → 434 locations
2026-05-16
Primary completion pushed: 2026-12-30 → 2027-06-30
2026-05-16
Completion pushed: 2026-12-30 → 2027-06-30
Trial Details
NCT Number NCT04849728
Lead Sponsor Inventiva Pharma
Conditions NASH - Nonalcoholic Steatohepatitis
Enrollment 1,000 participants
Start Date 2021-08-19
Primary Completion 2027-09-30 (estimated)
Study Completion 2027-09-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-02